Summit Therapeutics Inc. - 8-K Filing

Summit Therapeutics announced interim Phase II trial data for ivonescimab in first-line metastatic colorectal cancer showing an objective response rate of 70.8% and a durable duration of response, with no new safety signals observed.

SEC EDGAR · June 1, 2026, 10:58 UTC

Tickers: $SMMT

Read the full article at SEC EDGAR

More Regulatory news

LiveOne, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:45 UTC
Solana Co - 10-Q Filing SEC EDGAR · November 12, 2026, 13:42 UTC
Solana Co - 8-K Filing SEC EDGAR · November 12, 2026, 13:41 UTC
DeFi Development Corp. - 8-K Filing SEC EDGAR · November 12, 2026, 13:41 UTC
Stablecoin Development Corp - 8-K Filing SEC EDGAR · November 12, 2026, 13:40 UTC
BCP Investment Corp - 8-K Filing SEC EDGAR · November 12, 2026, 13:36 UTC
OneWater Marine Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:37 UTC
Moleculin Biotech, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:37 UTC
Investcorp Credit Management BDC, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:37 UTC
Presurance Holdings, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 13:35 UTC